Evicenter
P&T meetings

Anaphylm

Type I allergic reactions including anaphylaxis

Also known as dibutepinephrine, AQST-109
Regulatory submission
NDA resubmitted September 2026
Launch
Not announced
121 sources

Section 6 of 6

References

121 sources

  1. Acaster et al. (2020) (opens in a new tab)
  2. Adamis Pharmaceuticals (2021) (opens in a new tab)
  3. Alsaggaf et al. (2019) (opens in a new tab)
  4. Aquestive Therapeutics AAAAI poster presentations (2023) (opens in a new tab)
  5. Aquestive Therapeutics complete response letter announcement (2026) (opens in a new tab)
  6. Aquestive Therapeutics corporate presentation (2026) (opens in a new tab)
  7. Aquestive Therapeutics EPIPHAST II results (2022) (opens in a new tab)
  8. Aquestive Therapeutics EPIPHAST Part 1 results (2022) (opens in a new tab)
  9. Aquestive Therapeutics EPIPHAST Part 2 results (2022) (opens in a new tab)
  10. Aquestive Therapeutics EPIPHAST Part 3 final results (2022) (opens in a new tab)
  11. Aquestive Therapeutics EPIPHAST Part 3 initial results (2022) (opens in a new tab)
  12. Aquestive Therapeutics Form 10-K (2026) (opens in a new tab)
  13. Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026) (opens in a new tab)
  14. Aquestive Therapeutics investor day presentation (2021) (opens in a new tab)
  15. Aquestive Therapeutics investor presentation (2026) (opens in a new tab)
  16. Aquestive Therapeutics NDA acceptance announcement (2025) (opens in a new tab)
  17. Aquestive Therapeutics NDA resubmission announcement (2026) (opens in a new tab)
  18. Aquestive Therapeutics oral allergy syndrome study presentation (2024) (opens in a new tab)
  19. Aquestive Therapeutics oral allergy syndrome study results (2024) (opens in a new tab)
  20. Aquestive Therapeutics patent US 12,427,121 (2025) (opens in a new tab)
  21. Aquestive Therapeutics pediatric study results (2025) (opens in a new tab)
  22. Aquestive Therapeutics phase 1 topline results (2021) (opens in a new tab)
  23. Aquestive Therapeutics phase 3 first participant dosed (2023) (opens in a new tab)
  24. Aquestive Therapeutics phase 3 topline results (2024) (opens in a new tab)
  25. Aquestive Therapeutics pre-IND response (2021) (opens in a new tab)
  26. Aquestive Therapeutics second quarter 2026 earnings presentation (2026) (opens in a new tab)
  27. Aquestive Therapeutics second quarter 2026 results (2026) (opens in a new tab)
  28. Aquestive Therapeutics self-administration study results (2024) (opens in a new tab)
  29. Aquestive Therapeutics temperature and pH study results (2024) (opens in a new tab)
  30. Aquestive Therapeutics Type A meeting completion (2026) (opens in a new tab)
  31. Armstrong et al. (2013) (opens in a new tab)
  32. Arroyo et al. (2021) (opens in a new tab)
  33. ARS Pharmaceuticals (2024) (opens in a new tab)
  34. ARS Pharmaceuticals (2025) (opens in a new tab)
  35. ARS Pharmaceuticals (2026) (opens in a new tab)
  36. ARS Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  37. ASHP (2026) (opens in a new tab)
  38. Baseggio Conrado et al. (2021) (opens in a new tab)
  39. Bekis Bozkurt and Pençe (2025) (opens in a new tab)
  40. Bilaver et al. (2016) (opens in a new tab)
  41. Bilaver et al. (2019) (opens in a new tab)
  42. Blumenthal et al. (2018) (opens in a new tab)
  43. Brettig et al. (2025) (opens in a new tab)
  44. Bunke et al. (2025) (opens in a new tab)
  45. Cardona et al. (2020) (opens in a new tab)
  46. Centers for Medicare and Medicaid Services NADAC (2025) (opens in a new tab)
  47. Centers for Medicare and Medicaid Services NADAC (2026) (opens in a new tab)
  48. Chowdhury et al. (2026) (opens in a new tab)
  49. ClinicalTrials.gov NCT06527937 (opens in a new tab)
  50. ClinicalTrials.gov NCT07703982 (opens in a new tab)
  51. Commins (2017) (opens in a new tab)
  52. DailyMed NEFFY label (2026) (opens in a new tab)
  53. Dribin (2026) (opens in a new tab)
  54. Dribin et al. (2022) (opens in a new tab)
  55. Dribin et al. (2023) (opens in a new tab)
  56. Dribin et al. (2025) (opens in a new tab)
  57. Ellorin and Agrawal (2026) (opens in a new tab)
  58. Engel et al. (2025) (opens in a new tab)
  59. Fortune Business Insights (2026) (opens in a new tab)
  60. Golden et al. (2023) (opens in a new tab)
  61. Golden et al. (2026) (opens in a new tab)
  62. Golding et al. (2022) (opens in a new tab)
  63. Greenhawt and Shaker (2019) (opens in a new tab)
  64. Gupta et al. (2013) (opens in a new tab)
  65. Gupta et al. (2018) (opens in a new tab)
  66. Gupta et al. (2019) (opens in a new tab)
  67. Gurkha et al. (2023) (opens in a new tab)
  68. Herbert et al. (2021) (opens in a new tab)
  69. Hirata et al. (2024) (opens in a new tab)
  70. Höfer et al. (2024) (opens in a new tab)
  71. Iglesia et al. (2024) (opens in a new tab)
  72. Jeong and Lee (2023) (opens in a new tab)
  73. Jerschow et al. (2014) (opens in a new tab)
  74. Jiang et al. (2023) (opens in a new tab)
  75. Jimenez-Garcia et al. (2024) (opens in a new tab)
  76. Kraus et al. (2025) (opens in a new tab)
  77. Lee (2020) (opens in a new tab)
  78. Lee et al. (2015) (opens in a new tab)
  79. Lee et al. (2016) (opens in a new tab)
  80. Lieberman et al. (2021) (opens in a new tab)
  81. Lieberman et al. (2023) (opens in a new tab)
  82. Ma et al. (2014) (opens in a new tab)
  83. McKenzie et al. (2026) (opens in a new tab)
  84. McMurray et al. (2025) (opens in a new tab)
  85. Nasser et al. (2026) (opens in a new tab)
  86. Nduwimana et al. (2025) (opens in a new tab)
  87. Newman et al. (2022) (opens in a new tab)
  88. Nguyen et al. (2021) (opens in a new tab)
  89. Nowak-Wegrzyn et al. (2026) (opens in a new tab)
  90. Oppenheimer et al. (2022) (opens in a new tab)
  91. Patel et al. (2011) (opens in a new tab)
  92. Pouessel and Neukirch (2025) (opens in a new tab)
  93. Poziomkowska-Gęsicka and Kurek (2020) (opens in a new tab)
  94. Pühringer et al. (2023) (opens in a new tab)
  95. Ray et al. (2024) (opens in a new tab)
  96. Robinson et al. (2021) (opens in a new tab)
  97. Sampson et al. (2006) (opens in a new tab)
  98. Sato et al. (2025) (opens in a new tab)
  99. Shaker and Greenhawt (2018) (opens in a new tab)
  100. Shaker and Greenhawt (2019a) (opens in a new tab)
  101. Shaker and Greenhawt (2019b) (opens in a new tab)
  102. Shaker et al. (2017) (opens in a new tab)
  103. Shaker et al. (2021) (opens in a new tab)
  104. Shaker et al. (2025) (opens in a new tab)
  105. Sim et al. (2025) (opens in a new tab)
  106. Sindher et al. (2024) (opens in a new tab)
  107. Smith et al. (2026) (opens in a new tab)
  108. Spergel et al. (2026) (opens in a new tab)
  109. Spolidoro et al. (2023) (opens in a new tab)
  110. Turner et al. (2016) (opens in a new tab)
  111. Turner et al. (2017) (opens in a new tab)
  112. Viatris (2026) (opens in a new tab)
  113. Volerman et al. (2022) (opens in a new tab)
  114. Warren et al. (2018) (opens in a new tab)
  115. Warren et al. (2020) (opens in a new tab)
  116. Warren et al. (2021) (opens in a new tab)
  117. Warren et al. (2023) (opens in a new tab)
  118. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026) (opens in a new tab)
  119. Worm et al. (2025) (opens in a new tab)
  120. Yin et al. (2025) (opens in a new tab)
  121. Zhang et al. (2025) (opens in a new tab)